Rivaroxaban是什么？

Drug introduction about Rivaroxaban:

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor For the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery. No dose adjustment is required in elderly patients (>65 years).

Approved for marketing in Canada and the European Union in October 2008, Rivaroxaban is the world's first oral direct factor Xa inhibitor that can highly selectively and competitively inhibit free and bound factor It has the characteristics of high bioavailability, wide spectrum of disease treatment, stable dose-effect relationship, convenient oral administration and low risk of bleeding.

The biggest advantage of Rivaroxaban compared to warfarin is that it is not affected by age and weight, does not need to test coagulation function, and has little impact on the liver. The main side effects are the possibility of bleeding, anemia, etc., but it cannot be used if you have a bleeding disorder. The main side effects are the possibility of bleeding, anemia, etc., but it cannot be used if you have a bleeding disorder.

Rivaroxaban is contraindicated in: patients who are allergic to Rivaroxaban or any excipients; patients with clinically significant active bleeding; and patients with liver disease who have coagulation abnormalities and a risk of clinically relevant bleeding.

For patients with non-valvular atrial fibrillation, the recommended dose of Rivaroxaban is 20 mg once a day. For patients with low body weight (≤50kg) and elderly patients (>75 years old), doctors may reduce the dose to 15mg once a day at the discretion of the doctor. Rivaroxaban 10mg can be taken on an empty stomach, while Rivaroxaban 15mg and 20mg doses should be taken with food.